Ionis Pharmaceuticals, Inc. Q2 FY26 Results — Earnings Call Analysis
Published 30 May 2026 | Biotechnology | Market Cap: ₹12.8K Cr
- DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics and new starts; steady growth anticipated beyond 2026. - Ionis raised its 2026 total revenue guidance to $875 million to $900 million, an increase of $75 million versus prior guidance.
From Ionis Pharmaceuticals, Inc.'s Q2 FY26 earnings-call transcript · updated 30 May 2026.
Price
₹77.33
Market Cap
₹12.8K Cr
Revenue Rank
Margin Rank
How does Ionis Pharmaceuticals, Inc. rank in Biotechnology?
Compare Ionis Pharmaceuticals, Inc. against every Biotechnology company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 2- →DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics and new starts; steady growth anticipated beyond 2026.
- →Tryngolza (FCS) product sales guidance remains $100M-$110M for 2026, with strong Q1 demand suggesting growth momentum.
- →SHTG launch (olezarsen) planned for mid-2026 with $100M-$110M revenue estimate; broader patient access and payer coverage expected to expand in 2027, driving further growth.
- →Peak revenue for Tryngolza and SHTG combined projected at $3B+, up from prior $2B estimate due to updated pricing and payer research.
- →Collaborative revenues expected to rise, with total 2026 revenue guidance raised to $875M-$900M, including commercial and R&D milestones.
- →Operating expenses to increase moderately; focus on financial discipline and operating leverage improvement.
- →Expect cash flow breakeven by 2028 with continued investment in pipeline and launches.
📈 Profitability & Margins
Rank 3- →Ionis raised its 2026 total revenue guidance to $875 million to $900 million, an increase of $75 million versus prior guidance.
- →Commercial revenue is expected to weigh slightly more than R&D revenue within total revenue.
- →Product sales guidance for 2026: Tryngolza between $100 million and $110 million; DAWNZERA between $110 million and $120 million.
- →Operating expenses for 2026 expected to increase in the low-teen percentage range, driven primarily by sales, marketing, and launch readiness activities.
- →R&D expenses projected to remain steady compared to last year.
- →Non-GAAP operating loss forecasted between $425 million and $475 million for 2026, showing a $75 million improvement over previous guidance.
- →Company targets cash flow breakeven by 2028, indicating improving profitability trends beyond 2026.
🏗️ Capital Expenditure Plans
No information- →Ionis is making continued **strategic investments** to maximize the value of commercial medicines and pipeline.
- →Operating expenses are increasing primarily due to **commercial investments** supporting Tryngolza and DAWNZERA.
- →Investments also support **launch readiness activities** for olezarsen (SHTG) and zilginersen (Alexander’s disease).
- →Financial discipline is emphasized, with a low-teen percentage increase in operating expenses compared to last year.
- →Resources are being **redeployed toward late-stage pipeline drugs** fueling the next phase of growth.
- →Strong balance sheet (~$1.9 billion cash at Q1-end) supports continuing strategic investments.
- →Overall financial outlook reflects **accelerating commercial launches, advancing pipeline, and diversified revenue**, positioning for sustained growth and breakeven cash flow by 2028.
💰 Fundraising & Capital Structure
No information- →The company ended Q1 2026 with approximately $1.9 billion in cash.
- →$633 million was used to repay 0% convertible notes due on April 1, 2026.
- →The strong balance sheet and prudent fiscal management support ongoing strategic investments.
- →There is no mention of any planned or upcoming fundraising through debt or equity in the current disclosures.
- →Focus appears to be on using existing cash and diversified revenue streams to fund operations and launches.
- →Cash balance is projected to remain above $1.6 billion by year-end 2026 after debt repayment.
- →The company aims for cash flow breakeven by 2028, implying no near-term plans for additional financing rounds have been indicated.
📋 Order Book & Pipeline
Yes- →Demand for Tryngolza (for FCS) is very strong, with Q1 2026 being the best quarter to date in terms of patient starts and scripts.
- →DAWNZERA is experiencing strong early market uptake with increasing prescriptions from both new patients and switches from existing prophylactic therapies.
- →For DAWNZERA in 2026, guidance is $110 million to $120 million, reflecting steady order growth driven by switches.
- →Olezarsen (for severe hypertriglyceridemia, SHTG) launch expected in mid-2026 with an initial revenue guidance of $100 million to $110 million, growing steadily over time as more patients are identified.
- →Priority review for olezarsen with a PDUFA date of June 30, 2026, supports anticipated early demand buildup.
- →Zilganersen (for Alexander's disease) launch planned later in 2026 focusing initially on patients from clinical trials and expanded access programs, with ongoing efforts to identify additional patients.
- →Overall, order momentum and patient demand are strong across multiple products heading into 2026.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Biotechnology this season
- Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
- BridgeBio Pharma, Inc. (Q2 FY26)
BridgeBio Pharma, Inc. Q2 FY26 quarterly results analysis. Attruby franchise shows durable growth with a 24% increase in net sales from Q4 and 392% YoY growth i
Frequently Asked Questions
What were Ionis Pharmaceuticals, Inc. Q2 FY26 results?
- DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics and new starts; steady growth anticipated beyond 2026. - Ionis raised its 2026 total revenue guidance to $875 million to $900 million, an increase of $75 million versus prior guidance.
What is Ionis Pharmaceuticals, Inc. share price analysis?
Ionis Pharmaceuticals, Inc. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of -122.3 with a market cap of $12,780. Investors should review the full earnings analysis for detailed insights.
Is Ionis Pharmaceuticals, Inc. planning capital expenditure?
- Ionis is making continued **strategic investments** to maximize the value of commercial medicines and pipeline.
Keep Ionis Pharmaceuticals, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.